Advice to delegates attending FCTC COP-10

Article providing five-part advice to officials attending FCTC COP-10.

Senior officials should approach COP10 with scepticism but not cynicism, with clarity about their national goals and with some tough questions about trade-offs, unintended consequences and evidence.

Priorities for European Union regulation

Write-up of European THR Advocates (ETHRA) input into future EU Tobacco Product Directive for the European Commission. Damian Sweeney and I were interviewed by Open Evidence.

US strategy on smoking cessation

The US Department of Health and Human Services is consulting on a new national smoking cessation framework. David Sweanor and I responded, making the case for tobacco harm reduction as the game-changing strategy.

The case for tobacco harm reduction

Interview on the essentials of tobacco harm reduction: Клајв Бејтс: Алтернативите без чад имаат далеку помалку токсини од класичните цигари, Republika

Background on tobacco harm reduction for the US Supreme Court

The brief of amici curiae is filed in support of the Petition for writ of certiorari to the US Supreme Court made by Avail Vapor (a request for the Court to hear the substantive case). It covers seven main scientific arguments pertinent to the petition. Signed by David Abrams, Scott Ballin, Clive Bates, Martin Jarvis, Tom Miller, Ray Niaura, Steve Schroeder and David Sweanor.

FDA’s approach to regulatory strategy

24 public health experts respond to the Reagan-Udall Foundation evaluation of FDA’s Center for Tobacco Products and its policymaking and practice. RUF suggests that there is a void where there should be a strategy. We suggest a strategic framework with four main pillars and four supporting actions. The response is discussed in greater detail at this blog: Rethinking U.S. tobacco and nicotine regulation (part 2)

Rethinking nicotine the place of nicotine in society

I make the case that tobacco harm reduction is an interim phase contingent on the great harm caused by cigarettes. To see clearly where we are heading in the longer term, we need to rethink nicotine as a recreational drug with relatively low levels of harm.

Scroll to Top